Tissue Collection to Explore Genetic Alterations & ATM Protein Loss
Research type
Research Study
Full title
A Tissue Collection Study to Explore the Correlation Between ATM Genetic Alterations by Next-Generation Sequencing and ATM Loss-of-Protein via IHC (ATR-ID study)
IRAS ID
302814
Contact name
Hendrik-Tobias Arkenau
Contact email
Sponsor organisation
Artios Pharma Limited
Clinicaltrials.gov Identifier
Pending, clinicaltrials.gov (NCT Number)
Duration of Study in the UK
0 years, 7 months, 31 days
Research summary
The objective of this study is to see how a genetic change (mutation) in a gene called ATM, which plays a role in the repair of DNA, may affect tumours. Proteins are made by cells based on the DNA code and a mutation in the ATM gene might affect how or if cancer cells make the ATM protein. Some DNA mutations may not affect the ATM protein at all. Other mutations may not allow you to make (or express) the ATM protein in your tumor. In this study, we will test your tumor tissue to see how the genetic mutation that you have in the ATM gene affects the ATM protein in your tumor. The information collected from this study will help researchers understand whether people who have changes in their ATM gene may be more likely to benefit from a medicine that is being developed.
REC name
London - Central Research Ethics Committee
REC reference
21/PR/1101
Date of REC Opinion
1 Sep 2021
REC opinion
Favourable Opinion